Back to results
US 2009/0022828 A1Published application
Methods and compositions for inhibiting angiotensin converting and chymase enzymes
OwnerAfa Kehaati Palu, Chen Su +3inventors
InventorsAfa Kehaati Palu, Chen Su, Bing-Nan Zhou, Stephen Story, Claude Jarake Jensen
Life of this patent
Estimating the term…
Abstract
The present invention relates to medicinal products, as well as to health and wellness food products, and particularly to a medicinal product or a health and wellness food product for inhibiting Angiotensin Converting Enzyme and Chymase enzyme pathways.
Claims12
1-7. (canceled)
A method to inhibit Angiotensin Converting Enzyme in mammals comprising the step of:
- preparing a formulation containing at least one processed Morinda citrifolia product present in an amount by weight between about 0.1 and 99 percent;
- quercetin present between 0.01-10 percent by weight;
- and rutin present between 0.01-10 percent by weight;
- and administering said formulation.
1 more element
A method of treating mammals comprising:
- administering a formulation containing at least one processed Morinda citrifolia product present in an amount by weight between about 0.1 and 99 percent, wherein the formulation is adapted inhibit Angiotensin Converting Enzyme.
A method of treating mammals comprising:
- administering a formulation containing a processed Morinda citrifolia product present in an amount by weight between about 0.1 and 99 percent, wherein the formulation is adapted to affect a mammal in a way selected from a list consisting of:
- inhibit Angiotensin Converting Enzyme, prevent complications of a primary disorder in patients wherein said complication results from Angiotensin Converting Enzyme activity, treat a primary disorder in patients wherein said disorder results from Angiotensin Converting Enzyme activity, prevent a primary disorder in patients wherein said disorder results from Angiotensin Converting Enzyme activity, inhibit a Chymase Enzyme, prevent complications of a primary disorder in patients wherein said complication results from Chymase Enzyme activity, treat a primary disorder in patients wherein said disorder results from Chymase Enzyme activity, prevent a primary disorder in patients wherein said disorder results from Chymase Enzyme activity, treat hypertension, prevent hypertension, prevent high blood pressure, treat high blood pressure, treat atherosclerosis, prevent atherosclerosis, prevent strokes, treat strokes, prevent heart failure, treat heart failure, prevent renal failure, treat renal failure, affect vasodilatation.
A formulation for treating mammals comprising:
- a processed Morinda citrifolia product present in an amount by weight between about 0.1 and 99 percent, wherein the formulation is adapted to affect a mammal in a way selected from a list consisting of:
- inhibit Angiotensin Converting Enzyme, prevent complications of a primary disorder in patients wherein said complication results from Angiotensin Converting Enzyme activity, treat a primary disorder in patients wherein said disorder results from Angiotensin Converting Enzyme activity, prevent a primary disorder in patients wherein said disorder results from Angiotensin Converting Enzyme activity, inhibit a Chymase Enzyme, prevent complications of a primary disorder in patients wherein said complication results from Chymase Enzyme activity, treat a primary disorder in patients wherein said disorder results from Chymase Enzyme activity, prevent a primary disorder in patients wherein said disorder results from Chymase Enzyme activity, treat hypertension, prevent hypertension, prevent high blood pressure, treat high blood pressure, treat atherosclerosis, prevent atherosclerosis, prevent strokes, treat strokes, prevent heart failure, treat heart failure, prevent renal failure, treat renal failure, affect vasodilatation.
Dependencies are inferred from the claim text.